Werewolf Therapeutics, Inc. Stock Price, News & Analysis

A groundbreaking clinical trial at HonorHealth Research Institute has demonstrated remarkable success in treating advanced skin cancer using Werewolf Therapeutics' WTX-124, a novel conditionally activated IL-2 pro-drug. A 73-year-old patient, Wayne Futch, who previously failed over 60 radiation treatments, achieved complete remission within 12 weeks of treatment and has remained cancer-free for over a year. The drug is engineered to activate specifically in the tumor microenvironment, potentially offering the benefits of IL-2 with reduced toxicity. This development is particularly significant as cutaneous squamous cell carcinoma affects over 1 million Americans annually, with nearly 40,000 cases advancing to difficult-to-treat stages and approximately 7,000 deaths in advanced/metastatic cases. The trial (NCT05660384) is being conducted across 10 national clinical sites, evaluating the drug both as monotherapy and in combination with pembrolizumab for patients who have failed standard treatments.

Werewolf Therapeutics (NASDAQ: HOWL) announced its participation in the Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit in Boston on May 15-16, 2025. Dr. Sameer Chopra, VP of Clinical Development, will present on May 15 at 4:15 PM ET, discussing "Tumor-activated INDUKINE Molecules: Improving the Therapeutic Index of Proinflammatory Cytokines for Cancer Immunotherapy." The presentation will showcase data from first-in-human clinical trials of IL-2 and IL-12 INDUKINE molecules, which have validated the company's approach to developing conditionally activated therapeutics for cancer treatment.

Werewolf Therapeutics (NASDAQ: HOWL) reported Q1 2025 financial results and provided key updates on its clinical programs. The company's lead candidate WTX-124 continues to progress in Phase 1/1b trials, with data readouts expected in H2 2025. The first patient was dosed in the Phase 1b/2 trial of WTX-330. Werewolf announced development of proprietary INDUCER™ T cell engager molecules, with a candidate expected by Q2 2025. Financially, the company reported $92.0M in cash, extending runway into Q4 2026. Q1 2025 saw a net loss of $18.1M compared to $16.2M in Q1 2024. R&D expenses were $13.1M, while G&A expenses were $4.9M. The company's WTX-124 demonstrated meaningful anti-tumor activity with tolerable safety profiles in checkpoint inhibitor-treated patients.

Werewolf Therapeutics (NASDAQ: HOWL) presented new preclinical data for WTX-921, its IL-10 INDUKINE molecule, at IMMUNOLOGY2025. The data demonstrates WTX-921's efficacy in treating Inflammatory Bowel Disease (IBD) through a mouse colitis model.

Key findings show that WTX-921 effectively prevents weight loss and reduces Disease Activity Index scores in the ACT animal model over 4 weeks. The treatment decreased immune cell infiltration and inflammatory cytokine levels in the colon. Importantly, WTX-921's optimized blocking domain prevents peripheral off-tissue effects of IL-10, addressing previous toxicity challenges in IL-10 therapies.

With an estimated 7 million people worldwide affected by IBD in 2024, WTX-921 represents a potential breakthrough as a first-of-its-kind targeted IL-10 therapy designed to overcome systemic toxicity issues while delivering anti-inflammatory benefits to inflamed colon tissue.

Werewolf Therapeutics (NASDAQ: HOWL), a biopharmaceutical company focused on developing conditionally activated therapeutics for cancer and immune-mediated conditions, has announced its participation in two major investor conferences in May 2025:

• The Citizens Life Sciences Conference on May 8, 2025, at 10:00am ET in New York Hilton Midtown
• The Bank of America Securities 2025 Health Care Conference on May 14, 2025, at 3:15pm PT at The Encore Hotel, Las Vegas

Management will participate in fireside chats at both events. Webcasts will be available on the company's investor relations website, with replays accessible for approximately 90 days after the conferences.

Werewolf Therapeutics (Nasdaq: HOWL) has appointed Steven Bloom as Chief Business Officer, bringing over 35 years of life sciences industry experience. Bloom joins from Vincerx Pharma, where he previously served as CBO, and has held senior positions at companies including Ziopharm Oncology, Verastem Oncology, and Eli Lilly.

The company is approaching key milestones in 2025, including interim dose expansion data from the WTX-124 Phase 1/1b clinical trial, which has shown durable confirmed responses in cancer patients. The trial results are expected to guide discussions with regulators on potential registrational pathways.

As part of his compensation package, Bloom received a stock option grant for 201,720 shares, vesting over four years, with 25% vesting after the first year and the remainder monthly over three years.

Werewolf Therapeutics (Nasdaq: HOWL), a biopharmaceutical company focused on developing conditionally activated therapeutics for cancer treatment and immune-mediated conditions, has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference.

The company's leadership, including President and CEO Daniel J. Hicklin, Ph.D., and Chief Medical Officer Randi Isaacs, M.D., will deliver a corporate overview on Monday, April 7, 2025, at 1:30 PM ET. The conference is scheduled for April 7-10, 2025.

Interested parties can access the live presentation through the company's investor relations website at investors.werewolftx.com/news-and-events/events. A replay will remain available for approximately 90 days after the event.

Werewolf Therapeutics (NASDAQ: HOWL) has reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical trials. The company expects full enrollment in cutaneous melanoma dose-expansion arms of the WTX-124 Phase 1/1b trial by H2 2025, with interim data release planned for Q4 2025.

Key financial metrics show cash and cash equivalents of $111.0 million as of December 31, 2024, expected to fund operations through Q2 2026. The company reported a net loss of $70.5 million for full year 2024, compared to $37.4 million in 2023. Research and development expenses increased to $56.4 million in 2024 from $41.8 million in 2023.

Clinical highlights include promising preliminary evidence of durable anti-tumor activity for WTX-124, with five objective responses reported. The company plans to meet with the FDA in H2 2025 to discuss potential registrational pathways. Additionally, Werewolf is on track to initiate a Phase 1/2 trial for WTX-330 by the end of Q1 2025.

Werewolf Therapeutics (Nasdaq: HOWL), a biopharmaceutical company focused on developing conditionally activated therapeutics for cancer treatment and immune-mediated conditions, has announced its participation in the upcoming 2025 Leerink Partners Global Biopharma Conference.

The company's leadership, including Daniel J. Hicklin, Ph.D., President and CEO, and Randi Isaacs, M.D., Chief Medical Officer, will engage in a fireside chat scheduled for Tuesday, March 11, 2025, from 11:20-11:50 AM in Studio 3. The conference will take place in Miami, Florida, from March 10-12, 2025.

Interested parties can access a live webcast of the presentation through the company's investor relations website. The recorded session will remain available for replay for 180 days following the event.